Editas Q1 net loss $76.1M ($0.92/share); cash $221M runway into Q2 2027

Editas Medicine, Inc.

2025-Q1 EPS reported -$0.92 revenue$4,658,000

Net loss $76.1M ($0.92 per share) vs $62.0M loss in Q1 2024; revenue $4.7M (up from $1.1M).
R&D expenses fell to $26.6M from $48.8M; restructuring charges $40.9M from reni-cel discontinuation.
Cash, equivalents, and marketable securities $221.0M; expected to fund operations into Q2 2027.
Amy Parison appointed CFO; previously SVP Finance and Corporate Controller at Editas since 2022.
Federal Circuit vacated PTAB decision on CRISPR/Cas9 patents; remanded for further review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.